These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
262 related articles for article (PubMed ID: 37174050)
1. Current Approaches for the Curative-Intent Surgical Treatment of Pancreatic Ductal Adenocarcinoma. Słodkowski M; Wroński M; Karkocha D; Kraj L; Śmigielska K; Jachnis A Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37174050 [TBL] [Abstract][Full Text] [Related]
2. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer]. Scheufele F; Friess H Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198 [TBL] [Abstract][Full Text] [Related]
3. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998 [TBL] [Abstract][Full Text] [Related]
4. Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. Gray S; de Liguori Carino N; Radhakrishna G; Lamarca A; Hubner RA; Valle JW; McNamara MG Eur J Surg Oncol; 2022 Jun; 48(6):1198-1208. PubMed ID: 35264307 [TBL] [Abstract][Full Text] [Related]
6. Role of surgery in pancreatic cancer. Buanes TA World J Gastroenterol; 2017 Jun; 23(21):3765-3770. PubMed ID: 28638216 [TBL] [Abstract][Full Text] [Related]
7. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. Javed AA; Wright MJ; Siddique A; Blair AB; Ding D; Burkhart RA; Makary M; Cameron JL; Narang A; Herman J; Zheng L; Laheru D; Weiss MJ; Wolfgang C; He J J Gastrointest Surg; 2019 Jan; 23(1):112-121. PubMed ID: 30242644 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome? Khakoo S; Petrillo A; Salati M; Muhith A; Evangelista J; Seghezzi S; Petrelli F; Tomasello G; Ghidini M Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503206 [TBL] [Abstract][Full Text] [Related]
10. Current Surgical Concepts and Future Perspectives in the Treatment of Borderline Resectable and Potentially Resectable Locally Advanced Pancreatic Cancer. Karamarković AR; Juloski JT Chirurgia (Bucur); 2022 Jun; 117(4):385-398. PubMed ID: 36049095 [TBL] [Abstract][Full Text] [Related]
11. Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma. Sulciner ML; Ashley SW; Molina G J Clin Med; 2022 Aug; 11(16):. PubMed ID: 36013111 [TBL] [Abstract][Full Text] [Related]
12. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. Murphy JE; Wo JY; Ryan DP; Jiang W; Yeap BY; Drapek LC; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Faris JE; Zhu AX; Goyal L; Lillemoe KD; DeLaney TF; Fernández-Del Castillo C; Ferrone CR; Hong TS JAMA Oncol; 2018 Jul; 4(7):963-969. PubMed ID: 29800971 [TBL] [Abstract][Full Text] [Related]
13. Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoma. Jain AJ; Maxwell JE; Katz MHG; Snyder RA Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627202 [TBL] [Abstract][Full Text] [Related]
14. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers. Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366 [TBL] [Abstract][Full Text] [Related]
16. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Shrestha B; Sun Y; Faisal F; Kim V; Soares K; Blair A; Herman JM; Narang A; Dholakia AS; Rosati L; Hacker-Prietz A; Chen L; Laheru DA; De Jesus-Acosta A; Le DT; Donehower R; Azad N; Diaz LA; Murphy A; Lee V; Fishman EK; Hruban RH; Liang T; Cameron JL; Makary M; Weiss MJ; Ahuja N; He J; Wolfgang CL; Huang CY; Zheng L Cancer Med; 2017 Jul; 6(7):1552-1562. PubMed ID: 28639410 [TBL] [Abstract][Full Text] [Related]
17. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M; BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786 [TBL] [Abstract][Full Text] [Related]
18. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596 [TBL] [Abstract][Full Text] [Related]
19. Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here? Tsvetkova EV; Asmis TR Curr Oncol; 2014 Aug; 21(4):e650-7. PubMed ID: 25089113 [TBL] [Abstract][Full Text] [Related]